Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 6/2013

01-06-2013 | Review Article

The evolving use of arsenic in pharmacotherapy of malignant disease

Authors: Athena Kritharis, Thomas P. Bradley, Daniel R. Budman

Published in: Annals of Hematology | Issue 6/2013

Login to get access

Abstract

For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely to involve apoptosis, generation of reactive oxygen species, inhibition of intracellular transduction pathways, and cell functions. Arsenic trioxide has received approval for use in patients with relapsed acute promyelocytic leukemia for remission induction. Arsenic has additionally shown activity in a range of solid tumors, myelodysplastic syndrome, multiple myeloma, and in autoimmune diseases. The following is a review of the history of arsenic, its cellular metabolism, pharmacology, genetic basis of disposition, associated toxicities, and clinical efficacy.
Literature
1.
Antman KH (2001) Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 6(Suppl 2):1–2PubMedCrossRef
2.
Doyle D (2009) Notoriety to respectability: a short history of arsenic prior to its present day use in haematology. Br J Haematol 145(3):309–317PubMedCrossRef
3.
4.
Liu JLY, Wu Q et al (2008) Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Pharmacol Exp Ther 326:363–368PubMedCrossRef
5.
Miller M (1998) Scientists explore use of arsenic in therapy. J Natl Cancer Inst 90(24):1866–1867PubMed
6.
Waxman S, Anderson KC (2001) History of the development of arsenic derivatives in cancer therapy. Oncologist 6(Suppl 2):3–10PubMedCrossRef
7.
8.
9.
Thorburn AL (1983) Paul Ehrlich: pioneer of chemotherapy and cure by arsenic (1854–1915). Brit J Vener Dis 59(6):404–405
10.
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10):3315–3324PubMed
11.
Anonymous (2001) Arsenic-based therapy benefits leukemia patients. FDA Consum 35 (1):4
12.
Anonymous (2004) Arsenic trioxide: new preparation. (2004) Acute promyelocytic leukaemia: encouraging results but persistent doubts. Prescrire Int 13 (72):135–137
13.
Amadori S, Fenaux P, Ludwig H, O’Dwyer M, Sanz M (2005) Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin 21(3):403–411. doi:10.​1185/​030079904X20349 PubMedCrossRef
14.
Anderson KC, Boise LH, Louie R, Waxman S (2002) Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 8(1):12–25PubMedCrossRef
15.
Berenson JR, Boccia R, Siegel D, Bozdech M, Bessudo A, Stadtmauer E, Talisman Pomeroy J, Steis R, Flam M, Lutzky J, Jilani S, Volk J, Wong SF, Moss R, Patel R, Ferretti D, Russell K, Louie R, Yeh HS, Swift RA (2006) Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 135(2):174–183. doi:10.​1111/​j.​1365-2141.​2006.​06280.​x PubMedCrossRef
16.
Bonati A, Rizzoli V, Lunghi P (2006) Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol 7(6):397–405PubMedCrossRef
17.
Campbell RA, Sanchez E, Steinberg JA, Baritaki S, Gordon M, Wang C, Shalitin D, Chen H, Pang S, Bonavida B, Said J, Berenson JR (2007) Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 138(4):467–478. doi:10.​1111/​j.​1365-2141.​2007.​06675.​x PubMedCrossRef
18.
Donelli A, Chiodino C, Panissidi T, Roncaglia R, Torelli G (2000) Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? Haematologica 85(9):1002–1003PubMed
19.
20.
Sekeres MA (2007) New data with arsenic trioxide in leukemias and myelodysplastic syndromes. Clin Lymphoma Myelom 8(Suppl 1):S7–S12CrossRef
21.
Huang SY, Chang CS, Tang JL, Tien HF, Kuo TL, Huang SF, Yao YT, Chou WC, Chung CY, Wang CH, Shen MC, Chen YC (1998) Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 103(4):1092–1095PubMedCrossRef
22.
Kwong YL, Todd D (1997) Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 89(9):3487–3488PubMed
23.
Moore DF, O’Callaghan CA, Berlyne G, Ogg CS, Davies HA, House IM, Henry JA (1994) Acute arsenic poisoning: absence of polyneuropathy after treatment with 2,3-dimercaptopropanesulphonate (DMPS). J Neurol Neurosurg Psychiatry 57(9):1133–1135PubMedCrossRef
24.
25.
Sankpal UT, Goodison S, Abdelrahim M, Basha R (2011) Targeting sp1 transcription factors in prostate cancer therapy. Med Chem 7(5):518–525PubMedCrossRef
26.
Das NK, Sengupta SR (2008) Arsenicosis: diagnosis and treatment. Indian J Dermatol Venereol Leprol 74(6):571–581PubMedCrossRef
27.
Sengupta SR, Das NK, Datta PK (2008) Pathogenesis, clinical features and pathology of chronic arsenicosis. Indian J Dermatol Venereol Leprol 74(6):559–570PubMedCrossRef
28.
Caldwell KL, Jones RL, Verdon CP, Jarrett JM, Caudill SP, Osterloh JD (2009) Levels of urinary total and speciated arsenic in the US population: National Health and Nutrition Examination Survey 2003–2004. J Expo Sci Environ Epidemiolo 19(1):59–68. doi:10.​1038/​jes.​2008.​32 CrossRef
29.
30.
31.
Liu Y, Zhang W, Zhang X, Qi Y, Huang D, Zhang Y (2011) Arsenic trioxide inhibits invasion/migration in SGC-7901 cells by activating the reactive oxygen species-dependent cyclooxygenase-2/matrix metalloproteinase-2 pathway. Exp Biol Med 236(5):592–597. doi:10.​1258/​ebm.​2011.​010276 CrossRef
32.
Liu Q, Zhang H, Smeester L, Zou F, Kesic M, Jaspers I, Pi J, Fry RC (2010) The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics 3:37. doi:10.​1186/​1755-8794-3-37 PubMedCrossRef
33.
34.
Jang M, Kim Y, Won H, Lim S, K.R J, Dashdorj A, Min YH, Kim S-Y, Shokat KM, Ha J, Kim SS (2012) Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide, vol 72. First published. doi:10.​1158/​0008-5472.​can-12-1110
35.
Binet F, Girard D (2008) Novel human neutrophil agonistic properties of arsenic trioxide: involvement of p38 mitogen-activated protein kinase and/or c-jun NH2-terminal MAPK but not extracellular signal-regulated kinases-1/2. J Leukoc Biol 84(6):1613–1622. doi:10.​1189/​jlb.​0708421 PubMedCrossRef
36.
37.
Stepnik M, Ferlinska M, Smok-Pieniazek A, Gradecka-Meesters D, Arkusz J, Stanczyk M (2011) Assessment of the involvement of oxidative stress and mitogen-activated protein kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leukemic cell lines. Med Oncol. doi:10.​1007/​s12032-011-9920-1
38.
Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88(3):1052–1061PubMed
39.
40.
Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z, Chen GQ (2000) Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14(2):262–270PubMedCrossRef
41.
Meng R, Zhou J, Sui M, Li Z, Feng G, Yang B (2010) Arsenic trioxide promotes mitochondrial DNA mutation and cell apoptosis in primary APL cells and NB4 cell line. Science China Life Sciences 53(1):87–93. doi:10.​1007/​s11427-010-0004-9 PubMedCrossRef
42.
Lu D, Bai XC, Gui L, Li M, Zheng WS, Han XQ, Luo SQ (2003) Arsenic trioxide-induced apoptosis of human malignant lymphoma cell lines and its mechanisms. Di Yi Jun Yi Da Xue Xue Bao 23(10):997–1001PubMed
43.
44.
45.
46.
Liu Y, Hock JM, Sullivan C, Fang G, Cox AJ, Davis KT, Davis BH, Li X (2010) Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J Cell Biochem 111(6):1546–1555. doi:10.​1002/​jcb.​22886 PubMedCrossRef
47.
48.
Kim J, Lee JJ, Gardner D, Beachy PA (2010) Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. PNAS 107(30):13432–13437. doi:10.​1073/​pnas.​1006822107 PubMedCrossRef
49.
50.
51.
52.
Aballay LR, Diaz MD, Francisca FM, Munoz SE (2011) Cancer incidence and pattern of arsenic concentration in drinking water wells in Cordoba, Argentina. Int J Environ Health Res. doi:10.​1080/​09603123.​2011.​628792
53.
54.
Le XC, Lu X, Ma M, Cullen WR, Aposhian HV, Zheng B (2000) Speciation of key arsenic metabolic intermediates in human urine. Anal Chem 72(21):5172–5177PubMedCrossRef
55.
Carney DA (2008) Arsenic trioxide mechanisms of action—looking beyond acute promyelocytic leukemia. Leuk Lymphoma 49(10):1846–1851PubMedCrossRef
56.
Cui X, Kobayashi Y, Akashi M, Okayasu R (2008) Metabolism and the paradoxical effects of arsenic: carcinogenesis and anticancer. Curr Med Chem 15(22):2293–2304PubMedCrossRef
57.
Ghosh P, Banerjee M, Giri AK, Ray K (2008) Toxicogenomics of arsenic: classical ideas and recent advances. Mutat Res 659(3):293–301PubMedCrossRef
58.
Hernandez A, Marcos R (2008) Genetic variations associated with interindividual sensitivity in the response to arsenic exposure. Pharmacogenomics 9(8):1113–1132PubMedCrossRef
59.
Tseng CH (2007) Metabolism of inorganic arsenic and non-cancerous health hazards associated with chronic exposure in humans. J Environ Biol 28(2 Suppl):349–357PubMed
60.
Tseng CH (2007) Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25(1):1–22PubMedCrossRef
61.
Vahter M, Akesson A, Liden C, Ceccatelli S, Berglund M (2007) Gender differences in the disposition and toxicity of metals. Environ Res 104(1):85–95PubMedCrossRef
62.
Ghosh P, Banerjee M, Giri AK, Ray K (2008) Toxicogenomics of arsenic: classical ideas and recent advances. Mutat Res 659(3):293–301PubMedCrossRef
63.
Thomas DJ, Li J, Waters SB, Xing W, Adair BM, Drobna Z, Devesa V, Styblo M (2007) Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp Biol Med 232(1):3–13
64.
65.
66.
Styblo M, Del Razo LM, LeCluyse EL, Hamilton GA, Wang C, Cullen WR, Thomas DJ (1999) Metabolism of arsenic in primary cultures of human and rat hepatocytes. Chem Res Toxicol 12(7):560–565. doi:10.​1021/​tx990050l PubMedCrossRef
67.
Hirano S, Kobayashi Y, Cui X, Kanno S, Hayakawa T, Shraim A (2004) The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds. Toxicol Appl Pharmacol 198(3):458–467PubMedCrossRef
68.
Waters SB, Devesa V, Fricke MW, Creed JT, Styblo M, Thomas DJ (2004) Glutathione modulates recombinant rat arsenic (+3 oxidation state) methyltransferase-catalyzed formation of trimethylarsine oxide and trimethylarsine. Chem Res Toxicol 17(12):1621–1629. doi:10.​1021/​tx0497853 PubMedCrossRef
69.
Hirano S, Kobayashi Y, Cui X, Kanno S, Hayakawa T, Shraim A (2004) The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds. Toxicol Appl Pharmacol 198(3):458–467PubMedCrossRef
70.
Thomas DJ, Styblo M, Lin S (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176(2):127–144PubMedCrossRef
71.
Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG, Cruz-Gonzalez MB, Garcia-Montalvo EA, Calderon-Aranda ES, Del Razo LM (2005) Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect 113(3):250–254PubMedCrossRef
72.
Thomas DJ, Styblo M, Lin S (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176(2):127–144PubMedCrossRef
73.
Cohen SM, Arnold LL, Eldan M, Lewis AS, Beck BD (2006) Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit Rev Toxicol 36(2):99–133PubMedCrossRef
74.
Raml R, Rumpler A, Goessler W, Vahter M, Li L, Ochi T, Francesconi KA (2007) Thio-dimethylarsinate is a common metabolite in urine samples from arsenic-exposed women in Bangladesh. Toxicol Appl Pharmacol 222(3):374–380PubMedCrossRef
75.
Wang Z, Zhou J, Lu X, Gong Z, Le XC (2004) Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol 17(1):95–103PubMedCrossRef
76.
Lin CJ, Wu MH, Hsueh YM, Sun SS, Cheng AL (2005) Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective. Cancer Chemother Pharmacol 55(2):170–178PubMedCrossRef
77.
Hernandez-Zavala A, Matousek T, Drobna Z, Paul DS, Walton F, Adair BM, Jiri D, Thomas DJ, Styblo M (2008) Speciation analysis of arsenic in biological matrices by automated hydride generation-cryotrapping-atomic absorption spectrometry with multiple microflame quartz tube atomizer (multiatomizer). J Anal At Spectrom 23:342–351PubMedCrossRef
78.
Slejkovec Z, Falnoga I, Goessler W, van Elteren JT, Raml R, Podgornik H, Cernelc P (2008) Analytical artefacts in the speciation of arsenic in clinical samples. Anal Chim Acta 607(1):83–91PubMedCrossRef
79.
Schlawicke Engstrom K, Nermell B, Concha G, Stromberg U, Vahter M, Broberg K (2009) Arsenic metabolism is influenced by polymorphisms in genes involved in one-carbon metabolism and reduction reactions. Mutat Res 667:4–14
80.
Hernandez A, Xamena N, Surralles J, Sekaran C, Tokunaga H, Quinteros D, Creus A, Marcos R (2008) Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile. Mutat Res 637(1–2):80–92PubMed
81.
Fujihara J, Fujii Y, Agusa T, Kunito T, Yasuda T, Moritani T, Takeshita H (2009) Ethnic differences in five intronic polymorphisms associated with arsenic metabolism within human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Toxicol Appl Pharmacol 234(1):41–46PubMedCrossRef
82.
De Chaudhuri S, Ghosh P, Sarma N, Majumdar P, Sau TJ, Basu S, Roychoudhury S, Ray K, Giri AK (2008) Genetic variants associated with arsenic susceptibility: study of purine nucleoside phosphorylase, arsenic (+3) methyltransferase, and glutathione S-transferase omega genes. Environ Health Perspect 116(4):501–505PubMed
83.
Calderon RL, Hudgens E, Le XC, Schreinemachers D, Thomas DJ (1999) Excretion of arsenic in urine as a function of exposure to arsenic in drinking water. Environ Health Perspect 107(8):663–667PubMedCrossRef
84.
Ghaffari SH, Rostami S, Bashash D, Alimoghaddam K, Ghavamzadeh A (2006) Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy. Ann Oncol 17(10):1553–1559. doi:10.​1093/​annonc/​mdl150 PubMedCrossRef
85.
86.
87.
Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, Li XS, Wu W, Xiong SM, Zhao WL, Tang W, Wu F, Liu YF, Niu C, Wang ZY, Chen SJ, Chen Z (2001) Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 15(5):735–741PubMedCrossRef
88.
Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B, Jalili M (2011) Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 29(20):2753–2757. doi:10.​1200/​JCO.​2010.​32.​2107 PubMedCrossRef
89.
Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116(19):3751–3757. doi:10.​1182/​blood-2010-02-269621 PubMedCrossRef
90.
Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H (2009) Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27(4):504–510. doi:10.​1200/​JCO.​2008.​18.​6130 PubMedCrossRef
91.
Gore SD, Gojo I, Sekeres MA, Morris L, Devetten M, Jamieson K, Redner RL, Arceci R, Owoeye I, Dauses T, Schachter-Tokarz E, Gallagher RE (2010) Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 28(6):1047–1053. doi:10.​1200/​JCO.​2009.​25.​5158 PubMedCrossRef
92.
Lo-Coco F AG, Orlando SM, Ferrara F, Vignetti M, Paola Fazi, Eros Di Bona, Giorgina S (2012) ATRA and arsenic trioxide (ATO) versus atra and idarubicin (AIDA) for newly diagnosed, non high-risk acute promyelocytic leukemia (APL): results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG. In: 54th ASH Annual Meeting and Exposition, Atlanta, GA
93.
Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z (2009) Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci 106(9):3342–3347. doi:10.​1073/​pnas.​0813280106 PubMedCrossRef
94.
Mathews BG V, Lakshmi KM et al (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107:2627–2632CrossRef
95.
Lu D-P, Qiu J-Y, Jiang B, Wang Q, Liu K-Y, Liu Y-R, Chen S-S (2002) Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report, vol 99. doi:10.​1182/​blood.​V99.​9.​3136
96.
97.
Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, Lau JS, Kwong YL (2011) Oral arsenic trioxide based maintenance regimens for first complete remission of acute promyelocytic leukemia: a ten-year follow-up study. Blood. doi:10.​1182/​blood-2011-05-354530
98.
Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, Surico N, Malavasi F, Ferrero E (2002) Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 73(1):61–73PubMedCrossRef
99.
Diaz Z, Colombo M, Mann KK, Su H, Smith KN, Bohle DS, Schipper HM, Miller WH Jr (2005) Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. Blood 105(3):1237–1245. doi:10.​1182/​blood-2004-05-1772 PubMedCrossRef
100.
Diaz Z, Laurenzana A, Mann KK, Bismar TA, Schipper HM, Miller WH Jr (2007) Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. Leukemia 21(10):2117–2127. doi:10.​1038/​sj.​leu.​2404891 PubMedCrossRef
101.
Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP (2011) Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 12(10)
102.
Zhang W, Wang L, Fan Q, Wu X, Wang F, Wang R, Ma Z, Yang J, Lu SH (2011) Arsenic trioxide re-sensitizes ER alpha-negative breast cancer cells to endocrine therapy by restoring ER alpha expression in vitro and in vivo. Oncol Rep 26(3):621–628. doi:10.​3892/​or.​2011.​1352 PubMed
103.
Alsina M (2003) Multiple myeloma: increasing our treatment options. Cancer Control 10(5):357–358PubMed
104.
105.
106.
Gan F, Cao B, Wu D, Chen Z, Hou T, Mao X (2011) Exploring old drugs for the treatment of hematological malignancies. Curr Med Chem 18(10):1509–1514PubMedCrossRef
107.
108.
Sanaat Z, Rezazadeh M, Vaez Gharamaleki J, Eivazi Ziae J, Esfahani A (2011) Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study. Acta Med Iran 49(8):504–508PubMed
109.
Wen J, Feng Y, Huang W, Chen H, Liao B, Rice L, Preti HA, Kamble RT, Zu Y, Ballon DJ, Chang CC (2010) Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 34(1):85–92. doi:10.​1016/​j.​leukres.​2009.​05.​024 PubMedCrossRef
110.
Munshi NCDR, Zangari M (1999) Marked anti-tumor effect of arsenic trioxide (As2O3) in high risk refractory multiple myeloma. Blood 94:123a
111.
112.
Merkel O, Heyder C, Asslaber D, Hamacher F, Tinhofer I, Holler C, Stocher M, Prokesch A, Papak C, Scheideler M, Trajanoski Z, Greil R (2008) Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med 86(5):541–552. doi:10.​1007/​s00109-008-0314-6 PubMedCrossRef
113.
Wetzler M, Andrews C, Ford LA, Tighe S, Barcos M, Sait SN, Block AW, Nowak NJ, Baer MR, Wang ES, Baumann H (2011) Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. Cancer 117(21):4831–4868. doi:10.​1002/​cncr.​26097 CrossRef
114.
115.
Li N, Song Y, Zhou J, Fang B (2012) Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia. J Hem and Oncol 5(61). doi:1069344–990823
116.
117.
Sigmon C, Patch S (2010) A pilot survey of in-service home arsenic tracked in from chromated copper arsenate-treated decks. J Environ Health 72(6):18–22
118.
Sengupta SR, Das NK, Datta PK (2008) Pathogenesis, clinical features and pathology of chronic arsenicosis. Indian J Dermatol Venereol Leprol 74(6):559–570PubMedCrossRef
119.
Lin CC, Pu YS, Hsu CH, Keng HY, Cheng AL, Yang CH (2008) Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma. Urol Oncol 26(6):659–661PubMedCrossRef
120.
Tseng CH, Huang YK, Huang YL, Chung CJ, Yang MH, Chen CJ, Hsueh YM (2005) Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol Appl Pharmacol 206(3):299–308PubMedCrossRef
121.
Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Takeshita A, Sugiyama S, Satoh H, Terada H, Ohno R (2000) Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133(11):881–885PubMedCrossRef
122.
Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, Wiernik PH, Chiaramida S (2001) Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97(5):1514–1516PubMedCrossRef
123.
Raffoux ERP, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL (2003) Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21(12):2326–2334PubMedCrossRef
124.
125.
Navas-Acien ASE, Pastor-Barriuso R et al (2008) Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA 200:814–822CrossRef
126.
Coronado-Gonzalez JA, Del Razo LM, Garcia-Vargas G, Sanmiguel-Salazar F, Escobedo-de la Pena J (2007) Inorganic arsenic exposure and type 2 diabetes mellitus in Mexico. Environ Res 104(3):383–389PubMedCrossRef
127.
Yen CC, Lu FJ, Huang CF, Chen WK, Liu SH, Lin-Shiau SY (2007) The diabetogenic effects of the combination of humic acid and arsenic: in vitro and in vivo studies. Toxicol Lett 172(3):91–105PubMedCrossRef
128.
Navas-Acien A, Silbergeld EK, Streeter RA, Clark JM, Burke TA, Guallar E (2006) Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect 114(5):641–648PubMedCrossRef
129.
Diaz-Villasenor A, Burns AL, Hiriart M, Cebrian ME, Ostrosky-Wegman P (2007) Arsenic-induced alteration in the expression of genes related to type 2 diabetes mellitus. Toxicol Appl Pharmacol 225(2):123–133PubMedCrossRef
130.
Kritharis A BT, Budman DR (2011) Association of diabetes mellitus with arsenic trioxide (ATO) evaluated in the treatment of acute promyelocytic leukemia (APL). Proc ASCO Abstract no. e19724
131.
132.
Agency USEP (1999) Integrated Risk Information System (IRIS) on Arsenic. National Center for Environmental Assessment, Office of Research and Development
133.
Chen CJ, Chuang YC, Lin TM, Wu HY (1985) Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 45(11 Pt 2):5895–5899PubMed
134.
Marshall G, Ferreccio C, Yuan Y, Bates MN, Steinmaus C, Selvin S, Liaw J, Smith AH (2007) Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 99(12):920–928. doi:10.​1093/​jnci/​djm004 PubMedCrossRef
135.
Mass MJ, Tennant A, Roop BC, Cullen WR, Styblo M, Thomas DJ, Kligerman AD (2001) Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol 14(4):355–361PubMedCrossRef
136.
137.
Cuzick J, Evans S, Gillman M, Price Evans DA (1982) Medicinal arsenic and internal malignancies. Br J Cancer 45(6):904–911PubMedCrossRef
138.
Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M (2010) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 28(24):3866–3871. doi:10.​1200/​JCO.​2010.​28.​5031 PubMedCrossRef
Metadata
Title
The evolving use of arsenic in pharmacotherapy of malignant disease
Authors
Athena Kritharis
Thomas P. Bradley
Daniel R. Budman
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 6/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1707-3

Other articles of this Issue 6/2013

Annals of Hematology 6/2013 Go to the issue

Original Article

A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components

Letter to the Editor

Oligoclonal reconstitution masquerading as myeloma relapse

Letter to the Editor

Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation

Letter to the Editor

Autoimmune hemolytic anemia with warm-reactive immunoglobulin M antibody in multicentric Castleman disease

Original Article

Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence—clinical implication and comparison between the West and the East

Letter to the Editor

Hodgkin’s lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits